Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)

Hip Fracture Clinical Trial

Official title:

Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty for Hip Fracture

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03451916
• Other study ID #: PLX-HF-01
• Status: Completed
• Phase: Phase 3
• Start date: July 26, 2018
• Est. completion date: September 6, 2023

Study information

• Verified date: September 2023
• Source: Pluristem Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objectives of this study are to assess the efficacy, safety, and tolerability of PLX-PAD intramuscular administration for the treatment of muscle injury following arthroplasty for HF.

Description:

This will be a Phase III, multinational, randomized, double-blind, placebo-controlled study, assessing the efficacy, safety, and tolerability of intramuscular (IM) administration of allogeneic PLX-PAD cells for the treatment of muscle injury following arthroplasty for HF as compared to placebo treatment. Both treatment arms will receive standard of care treatment per local practice. The study will comprise 2 periods: 1. Main study period - from Screening to 52 weeks post-treatment. During this period, the subjects will have the following study visits: Screening, Day 0 (treatment and surgery day), Day 1, Day 5, Week 6, Week 12, Week 26 and Week 52. 2. Safety follow-up period - from Week 52 to Week 104. During this safety follow-up period, there will be a phone call visit at Week 104 and Only survival and quality of life data, serious adverse events (SAEs) and new malignancy adverse events will be collected. The main study period will comprise 4 periods: 1. Screening and pre-surgery time 2. Surgery and treatment with PLX-PAD or placebo (Day 0) 3. Hospital follow-up until Day 5±1, at least 4. Follow-up period up to 52 weeks following study treatment administration. Subjects will be assessed for study eligibility before the emergency surgery for HF. After being found eligible, subjects will be randomized using a 1:1 allocation scheme to either 150×106 PLX-PAD cells or to placebo treatment, respectively. Within 48 hours of admission and up to 72 hours following fracture, subjects will undergo HA or THA. During the surgical procedure, the subjects will receive the investigational product in accordance with the treatment group to which they were randomized. Thereafter, visits will be conducted at Days 1 and 5±1, and at Weeks 6, 12, 26, 52 and 104.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 240
• Est. completion date: September 6, 2023
• Est. primary completion date: April 29, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 0 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects

2. Subjects up to 90 years of age, inclusive, at the time of Screening

3. Subjects suffering low energy trauma with intracapsular neck of femur fracture.

4. Planned to be treated with total hip arthroplasty (THA) or hemi-arthroplasty (HA) within 48 hours of hospital admission and 72 hours post fracture.

5. Subjects able to walk 10 feet/3 meters before the fracture.

6. Signed an informed consent.

Exclusion Criteria:

• 1. Any significant musculoskeletal, neurologic or neuromuscular disease causing muscle weakness and/or affecting mobility 2. Current fracture is due to bone pathology other than osteoporosis or due to major trauma 3. Planned orthopedic surgery on lower limbs (excluding hip arthroplasty) within the next 12 months.

4. Diabetes mellitus with HbA1c >10% at Screening. 5. Known current or history of proliferative retinopathy or diabetic retinopathy.

6. Known active Hepatitis B virus or Hepatitis C virus infection. 7. Known human immunodeficiency virus (HIV) infection, severe uncontrolled inflammatory disease or severe uncontrolled autoimmune disease (e.g., ulcerative colitis, Crohn's disease, etc).

8. Subjects on renal replacement therapy or with estimated glomerular filtration rate (eGFR) <15 mL/min/1.73m2 9. Severe congestive heart failure symptoms (New York Heart Association [NYHA] Stage IV).

10. Known uncontrolled severe hypertension. 11. Treatment with anabolic steroids within 6 months prior to study start 12. Active malignancy or history of malignancy within 3 years prior to study start 13. Known moderate to severe dementia or severe psychiatric disorder. 14. Known allergies to any of the following: dimethyl sulfoxide (DMSO), human serum albumin (HSA), bovine serum albumin, PlasmaLyte.

15. History of allergic/hypersensitivity reaction to any substance having required hospitalization and/or treatment with IV steroids/epinephrine 16. Pulmonary disease requiring supplemental oxygen treatment on a daily basis. 17. life expectancy of less than 6 months, for reasons other than HF complications, 18. Subject is currently enrolled in or has not yet completed a period of at least 30 days since ending other investigational device or drug trial(s).

19. In the opinion of the Investigator, the subject is unsuitable for participating in the study.

Related Conditions & MeSH terms

• Fractures, Bone
• Hip Fracture
• Hip Fractures

Intervention

Drug:
• PLX-PAD
PLX-PAD (120 subjects): 150×10^6 PLX-PAD cells (10×10^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte
• Placebo
Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO [v/v], 5% HSA [w/v], and PlasmaLyte, without cells).

Locations

Country	Name	City	State
Bulgaria	MHAT "Ljulin" Department of Orthopedy and Traumatology	Sofia
Bulgaria	MHAT "Serdika" Department of Orthopedy and Traumatology	Sofia
Bulgaria	Military Medical Academy	Sofia
Bulgaria	Specialized Hospital for Active Treatment in Orthopedy	Sofia
Germany	Charite - Campus Mitte,Campus Virchow-Klinikum	Berlin
Germany	Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden	Dresden
Germany	Universitaetsklinikum Muenster	Münster
Israel	Carmel Medical Center,7 Michal St	Haifa
Israel	Shaare Zedek Medical Center,The Orthopedic Department,Shmu'el Bait St. 12	Jerusalem
Israel	Meir Medical Center-Internal Medicine E;59 Tshernichovsky Street	Kfar-Saba
Israel	The Chaim Sheba Medical Center,Tel Hashomer	Ramat Gan
Israel	Kaplan Medical Center,Pasternak St., P.O.B 1,Rehovot	Re?ovot
Israel	Sourasky Medical Center,6 Weizmann St; Harrison Building 6 Floor	Tel Aviv
United Kingdom	John Radcliffe Hospital	Oxford
United States	Denver Metro Orthopedics, P.C. 499 E. Hampden Avenue, Suite 140 Englewood, CO 80113	Denver	Colorado
United States	ANTRIA, INC,300 Indian Springs Road,Indiana	Indiana	Pennsylvania
United States	University Of California Davis,4860 Y Street	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
Pluristem Ltd.

Countries where clinical trial is conducted

United States,  Bulgaria,  Germany,  Israel,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Short Physical Performance Battery (SPPB) score		Week 26.
Secondary	Hip abduction strength of the injured leg		Week 26.
Secondary	Change from baseline to Week 52 in lower extremity measure (LEM) (retrospective collection of pre-fracture LEM at Day 5±1).		baseline to Week 52
Secondary	SPPB score	The Short Physical Performance Battery (SPPB) is an objective assessment tool for evaluating lower extremities function. The SPPB consists of 3 types of physical maneuvers: balance test, speed gait test, and chair stand test. Results from each maneuvers test are scored on a scale of 0 to 4, with an increasing composite score indicating an improved lower extremities function level. The total maximum score of SPPB is 12.	Week 52.